SLU-PP-332

SLU-PP-332 is a groundbreaking synthetic small-molecule compound developed at Saint Louis University that functions as a pan-estrogen-related receptor (ERR) agonist with preferential activity at ERRα. Often called an 'exercise mimetic,' it activates metabolic pathways typically engaged during physical exercise without requiring actual physical activity. By enhancing mitochondrial biogenesis, fatty acid oxidation, and energy expenditure, SLU-PP-332 has demonstrated remarkable effects across multiple systems including weight loss (12% in 28 days), improved exercise capacity (70% increase in endurance), enhanced insulin sensitivity, cardiac protection, and reversal of age-related mitochondrial dysfunction. While showing tremendous promise in preclinical studies with favorable safety profiles in multiple animal models, it remains in research-only status with no human clinical trials yet conducted. Researchers at the University of Florida are working to advance this compound toward human studies and developing an oral pill formulation for easier administration.

• Weight Loss & Metabolic Syndrome
• Exercise Mimetic Effects
• Anti-Aging & Longevity

Exercise mimetic effects without physical activity, significant weight loss (12% in 28 days), 70% increased endurance, 25% enhanced fatty acid oxidation, improved insulin sensitivity, reduced hepatic steatosis, cardiac protection, reversal of age-related mitochondrial dysfunction, enhanced muscle oxidative capacity

Binds to and activates estrogen-related receptors (ERRα, ERRβ, ERRγ) which regulate gene expression for energy metabolism. Upregulates PGC-1α (master regulator of mitochondrial biogenesis), activates AMPK pathway (cellular energy switch), increases mitochondrial density up to 1.8-fold, enhances oxidative phosphorylation and ATP production, promotes fatty acid oxidation, induces type IIa oxidative muscle fiber genes, and activates acute aerobic exercise genetic programs.

Research protocols from published literature — not dosing recommendations.

• Metformin — Monitor Combination: Both affect mitochondrial function and AMPK pathways - combination may have additive metabolic effects. Monitor blood glucose closely as combined use could increase hypoglycemia risk.
• Insulin — Monitor Combination: SLU-PP-332 enhances insulin sensitivity and glucose metabolism - may require significant insulin dose reduction to prevent hypoglycemia. Close monitoring essential.
• Tirzepatide — Monitor Combination: Both compounds affect weight loss and metabolic parameters through different mechanisms - combination could have additive effects on weight loss and glucose control. Monitor for excessive metabolic changes.
• Semaglutide — Monitor Combination: Combining two weight loss mechanisms (GLP-1 + ERR agonism) may produce enhanced metabolic effects. Monitor weight loss rate and metabolic parameters closely.
• 5-Amino-1MQ — Compatible: Distinct mechanisms (ERR agonism vs NNMT inhibition) may be complementary for metabolic optimization without known interactions.
• NAD+ — Synergistic: Both enhance mitochondrial function through complementary pathways - SLU-PP-332 increases mitochondrial biogenesis while NAD+ supports mitochondrial energy production.
• CJC-1295 — Compatible: Growth hormone optimization (CJC-1295) may complement metabolic enhancement (SLU-PP-332) for body composition improvements without known interactions.
• Ipamorelin — Compatible: May help preserve lean muscle mass during SLU-PP-332-induced fat loss through GH pathway. No known negative interactions.

Supplies:

• DMSO (dimethyl sulfoxide) - required as primary solvent (50-125 mg/mL)
• PEG300, Tween 80, and PBS/saline as carriers for in vivo use
• Alternative: corn oil as carrier (10% DMSO + 90% corn oil)

1. 1This is a lipophilic small molecule, not a peptide - it will NOT dissolve in water-based solutions
2. 2Dissolve SLU-PP-332 in pure anhydrous DMSO first to create a stock solution (up to 50-125 mg/mL)
3. 3For in vivo use, dilute DMSO stock with carriers: 10% DMSO + 10% Tween 80 + 80% PBS (from published studies)
4. 4Alternative formulation: 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline
5. 5Oil-based alternative: 10% DMSO + 90% corn oil
6. 6Ensure solution is completely clear before adding each solvent - use vortex, ultrasound, or gentle warming
7. 7Final DMSO concentration should not exceed 10% for in vivo applications
8. 8Store DMSO stock solutions at -80°C (6 months) or -20°C (1 month) - avoid repeated freeze-thaw

Hours 1-6: Metabolic shift toward fat oxidation (decreased respiratory exchange ratio within 2 hours), Gene expression changes detectable at 3-6 hours, Measurable plasma (0.2 μM) and muscle (0.6 μM) concentrations at 6 hours, Enhanced exercise performance in acute dosing studies (1 hour post-dose). Week 1: Increased resting energy expenditure becomes measurable, Enhanced fatty acid oxidation (25% increase), Initial metabolic adaptations and mitochondrial remodeling begins, Improved grip strength becomes observable by day 6. Week 2-4: Significant weight loss (up to 12% by day 28 in animal studies), Fat mass reduction dramatically different from controls (<0.5g vs ~5g gain), Improved glucose tolerance and insulin sensitivity, Enhanced exercise endurance (45-70% improvements in running performance), Muscle fiber type changes toward oxidative phenotype, Reduced hepatic steatosis becomes evident. Week 6-8: Cardiac improvements evident (improved ejection fraction, reduced fibrosis), Structural cardiac and muscle remodeling continues, Reversal of age-related kidney dysfunction (if applicable), Restoration of mitochondrial architecture in multiple tissues, Reduced inflammatory and senescence markers in aging tissues. Long-term (5+ months): Sustained anti-aging effects observed in preclinical aging studies, Continued improvement in tissue mitochondrial function, Reversal of cellular senescence markers maintained, Duration of effects after discontinuation is UNKNOWN in humans, Whether tolerance develops with chronic use remains UNSTUDIED.

NOT FDA APPROVED - FOR RESEARCH USE ONLY. Animal studies show favorable safety profile with no severe side effects at therapeutic doses. Well-tolerated in rodents and canines with no liver, kidney, or cardiac toxicity. No adverse effects on pancreatic histology, lean mass, or body temperature regulation. Does not suppress hormones or act as a stimulant in animal models. Minor changes in plasma cholesterol and liver enzymes noted in some studies. High doses or prolonged exposure may have uncharacterized side effects. Potential effects on insulin sensitivity - may interact with diabetes medications. Human safety profile is COMPLETELY UNKNOWN - extrapolation from animals is unreliable. Legal status varies by jurisdiction - may be restricted or illegal in many areas. NEVER use experimental compounds without medical supervision and regulatory approval.

NOT FDA APPROVED - FOR RESEARCH USE ONLY. Animal studies show favorable safety profile with no severe side effects at therapeutic doses. Well-tolerated in rodents and canines with no liver, kidney, or cardiac toxicity. No adverse effects on pancreatic histology, lean mass, or body temperature regulation. Does not suppress hormones or act as a stimulant in animal models. Minor changes in plasma cholesterol and liver enzymes noted in some studies. High doses or prolonged exposure may have uncharacterized side effects. Potential effects on insulin sensitivity - may interact with diabetes medications. Human safety profile is COMPLETELY UNKNOWN - extrapolation from animals is unreliable. Legal status varies by jurisdiction - may be restricted or illegal in many areas. NEVER use experimental compounds without medical supervision and regulatory approval.

SLU-PP-332 should be stored at Research compound storage requirements vary.